CD38 and acute lymphoblastic leukemia: Among several antibodies being evaluated, the anti-CD38 monoclonal antibody daratumumab appears promising, as this target is overexpressed on T-ALL cells but expressed in very low levels on normal lymphoid and myeloid cells, and the antibody was very effective against T-ALL in human xenograft models [77].